|
|
Treatment-resistant depression: An untapped area of the patient populationPublished by: Datamonitor Published: Mar. 18, 2002 - 37 Pages Table of ContentsTABLE OF CONTENTS INTRODUCTION Overview of treatment-resistant depression EPIDEMIOLOGY Risk factors for TRD Prevalence of major depression Prevalence of TRD TREATMENT STRATEGIES Overview Switching strategies Effexor Wellbutrin Remeron Augmentation/combination strategies Augmentation strategy Combination strategy Non-pharmacological strategies Electroconvulsive therapy Vagus nerve stimulation THE FUTURE DECODED Developing augmentation therapy New entrants into the market Conclusion APPENDIX Contributing experts Bibliography References Websites DATAMONITOR HEALTHCARE © Datamonitor 2002. All Rights Reserved. AbstractIncreasingly, treatment-resistant depression (TRD) is becoming a focus for not just antidepressant manufacturers that operate in this market, but also healthcare providers, the media, national governments and patient groups. This is because TRD is being ever more recognized as a major problem within the overall treatment of major depression. In the literature surrounding this segment of the depression patient population, TRD is also known as refractory depression or intractable depression. Consequently, this market brief discusses the prevalence rate of TRD, illustrates the strategies employed by manufacturers of major antidepressant brands to gain access to this patient group, examines other strategies employed by psychiatrists, for example, augmentation or combination therapy, to treat this patient set and outlines Datamonitor’s recommendations for manufacturers of existing brands and those aiming to enter the market in how to maximize the revenues they accrue from this section of the patient population.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||